IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.
Saved in:
| Title: | IGLV3-21R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL. |
|---|---|
| Authors: | Yosifov DY; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.; German Cancer Research Center (DKFZ) Heidelberg Germany., Robrecht S; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany., Giza A; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany., Maity PC; Institute of Experimental Cancer Research Ulm University Medical Center Ulm Germany., Riecke A; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.; Internal Medicine, Division of Hematology German Military Hospital Ulm Ulm Germany., Schneider C; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.; Comprehensive Cancer Center Ulm (CCCU) Ulm University Hospital Ulm Germany., Jebaraj BMC; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany., Dheenadayalan RP; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany., Jumaa H; Institute of Immunology Ulm University Hospital Ulm Germany., Young M; Institute of Immunology Ulm University Hospital Ulm Germany., Kumar M; Institute of Experimental Cancer Research Ulm University Medical Center Ulm Germany., Müller L; Study Centrum Unter Ems Practice for Oncology and Hematology Leer Germany., Vehling-Kaiser U; Outpatient Clinic Landshut Germany., Eckart M; Onkologische Schwerpunktpraxis Erlangen Erlangen Germany., Freier W; Medicinum Hildesheim Germany., Schöttker B; Hämatologisch-onkologische Schwerpunktpraxis Würzburg Würzburg Germany., Gaska T; Brüderkrankenhaus St. Josef Paderborn Germany., Reiser M; Praxis Internistischer Onkologie und Hämatologie Frechen Germany., Fink AM; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany., Fischer K; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany., Eichhorst B; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany., Hallek M; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany., Langerbeins P; Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany.; German CLL Study Group University of Cologne Cologne Germany., Tausch E; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.; Comprehensive Cancer Center Ulm (CCCU) Ulm University Hospital Ulm Germany., Stilgenbauer S; Division of CLL, Department of Internal Medicine III Ulm University Hospital Ulm Germany.; Comprehensive Cancer Center Ulm (CCCU) Ulm University Hospital Ulm Germany. |
| Source: | HemaSphere [Hemasphere] 2026 Jun 15; Vol. 10 (6), pp. e70385. Date of Electronic Publication: 2026 Jun 15 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2572-9241 |
|---|---|
| DOI: | 10.1002/hem3.70385 |
